Blueshift Asset Management LLC Takes $521,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Blueshift Asset Management LLC acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,260 shares of the company’s stock, valued at approximately $521,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FSA Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the third quarter worth approximately $25,000. Rialto Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $30,000. Retirement Wealth Solutions LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $31,000. Kestra Investment Management LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $38,000. Finally, Crews Bank & Trust purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $41,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Activity

In related news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research reports. Barclays raised their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, March 15th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners started coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. Finally, Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Trading Down 0.4 %

IDEXX Laboratories stock opened at $420.62 on Friday. The stock has a market cap of $34.21 billion, a P/E ratio of 39.42, a PEG ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $548.88. The firm’s 50 day moving average price is $437.30 and its 200-day moving average price is $445.53.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.